Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) shares are rising Thursday after the company announced a multi-year collaboration with Tempus AI Inc (NASDAQ:TEM) to support the development of its oncology pipeline.
- WHWK stock is racing ahead of the pack. Check the market position here.
What To Know: Whitehawk and Tempus AI, a technology company using AI to advance precision medicine, will leverage Tempus AI’s proprietary real-world dataset to advance biomarker-driven research.
Under the agreement, Whitehawk will use Tempus’ de-identified multimodal database to inform clinical trial designs and identify patient populations with the highest levels of unmet need. The research will focus on Whitehawk's ADC portfolio, which includes three assets targeting clinically validated proteins — PTK7, MUC16 and SEZ6 — linked to cancer indications such as lung and gynecological cancers.
“A proactive approach to our biomarker strategy ensures our programs are guided by data-driven insights,” said Dave Lennon, president and CEO of Whitehawk Therapeutics.
“By partnering with Tempus, our goal is to better understand the expression of our ADC protein targets to inform indication prioritization for our clinical development programs and better exploit the full potential of our pipeline.”
How To Buy WHWK Stock
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Whitehawk's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
WHWK Price Action: At the time of publication, Whitehawk shares were up 32.48% at $2.78, according to data from Benzinga Pro.
Related Link:
Image via Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
